HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

the first HIV fusion inhibitor. [1] Coreceptor CCR5 antagonists, which provide a novel mechanism of action, are a recent addition to the armamentarium of antiretroviral agents. Maraviroc ...

Among the CCR5 inhibitors developed so far, maraviroc is the first drug that has been approved by the US FDA for treating patients with R5 HIV-1. Although many CXCR4 inhibitors, some of which are ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

The most common strain, called HIV-1 group M, accounts for around 95 per ... HIV infects cells by attaching to a protein on their surface, called CCR5. Some people have a genetic mutation that ...

Individuals carrying this variant exhibited lower CCR5 expression and lower rates of HIV-1 infection in their cells. Before initiating ART, VNPs showed significantly lower total and intact HIV-1 ...

This class of drugs works by blocking the protein shell of the HIV-1 virus, known as the capsid. Lenacapavir(Sunlenca) is initially given as oral tablets and subcutaneous injections, followed by ...

UCLA researchers presented today the first case of a U.S. woman living with HIV-1 that is in remission after she received a new combination of specialized stem cell transplants for treatment of acute ...